RLFTF News and Press, Mondobiotech Holding AG Basel From 06/20/23

GENEVA, SWITZERLAND / ACCESSWIRE / June 20, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to ...

Ad hoc announcement pursuant to Art. 53 LR GENEVA, SWITZERLAND / ACCESSWIRE / June 16, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFFD )(OTCQB: RLFTD ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with...

GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFFD )(OTCQB: RLFTD ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to b...

The state-of-the-art quality control and research and development laboratory in Balerna, Switzerland is run by APR Applied Pharma Research SA, a Relief Therapeutics subsidiary GENEVA, SWITZERLAND / ACCESSWIRE / May 15, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFFD )(OTCQB...

GENEVA / ACCESSWIRE / May 12, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFFD )(OTCQB: RLFTD ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those ...

GENEVA, SWITZERLAND / ACCESSWIRE / May 3, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suff...

Acer reports OLPRUVA™ drug availability anticipated in mid-June 2023; Acer is engaged in discussions with payers representing a substantial majority of covered lives; 70 percent of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at le...

Shareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated upon Nasdaq listing GENEVA, SWITZERLAND / ACCESSWIRE / April 28, 2023 / RELIEF THERAPEUTICS ...

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 ® (Aviptadil Acetate) Relief to file a revised provisional patent application for RLF-100 ® based on the new stability results GENEVA, SWITZERLAND / ACCESSWIRE...

2023-04-14 04:58:57 ET Relief Therapeutics Holding AG press release ( OTCQB:RLFTF ): FY GAAP EPS of CHF0.012. As of December 2022 had CHF22.56M in cash and cash equivalents. For further details see: Relief Therapeutics GAAP EPS of CHF0.01